24 February 2025 in Annals of Neurology
22 October 2021 in Future Microbiology
Aim: The purpose of our study was to assess the differences between HIV-negative cryptococcal meningitis (CM) patients with and without autoimmune diseases. Methods: A total of 43 CM patients with ...
19 August 2022 in Future Microbiology
Objective: We aimed to study the possible relationship between cryptococcal meningitis (CM) and HLA genotypes in HIV-negative immunocompetent patients. Methods: HLA loci of 53 HIV-negative immunoco... Plain language summary Cryptococcus neoformans is a pathogen that mainly causes infections in patients with a weakened immune system. The most common manifestation of C. neoformans infection is cry...
21 August 2025 in British Journal of Clinical Pharmacology
1 January 2022 in SSRN Electronic Journal
Background: An increasing number of HIV-negative cryptococcal meningitis (CM) patients have been reported with fatality approaching 30%. At present, HIV-negative CM patients are stratified according to clinical guidelines and clinical experience for individualized treatment, but the effect seems to be not ideal in clinical practice. Therefore, an accurate model that predict the prognosis for HIV-negative CM patients is needed to provide reference for precision treatment. Methods: This retrospective study involved 490 HIV-negative CM patients diagnosed between January 1, 1998, and March 31, 2022, by neurologists from 3 tertiary Chinese centres. Prognosis was evaluated at 10 weeks after the initiation of antifungal therapy. We used least absolute shrinkage and selection operator (LASSO) for feature filtering and developed a machine learning (ML) model to predict the prognosis in HIV-negative CM patients. Fifty-six patients from 2 other hospitals were analysed for external validation. An artificial intelligence (AI)-based detection model was also developed to automate the rapid counting of microscopic cryptococcal counts. Results: The final prediction model for HIV-negative CM patients comprised 8 variables: CSF cryptococcal count, CSF white blood cell (WBC), altered mental status, hearing impairment, CSF chloride levels, CSF opening pressure (OP), aspartate aminotransferase levels at admission and decreased rate of CSF cryptococcal count within 2 weeks after admission. The areas under the curve (AUCs) in the internal and external validation sets were 0.87 (95% CI 0.794-0.944) and 0.86 (95% CI 0.744-0.975), respectively. An AI model was trained to detect and count cryptococci, and the mean average precision (mAP) was 0.993. Additionally, an online and freely available platform for predicting prognosis and detecting and counting cryptococci in HIV-negative CM patients was established. Interpretation: A ML model for predicting prognosis in HIV-negative CM patients was built and validated, and the model might provide a reference for personalized treatment of HIV-negative CM patients. The change in the CSF cryptococcal count in the early phase of HIV-negative CM treatment can reflect the prognosis of the disease. In addition, utilizing AI to detect and count CSF cryptococci in HIV-negative CM patients can eliminate the interference of human factors in detecting cryptococci in CSF samples and reduce the workload of the examiner. Funding Information: The study was supported by National Science Foundation (No. 82071265). Declaration of Interests: The authors declare that they have no competing interests. Ethics Approval Statement: All procedures performed in studies involving the patient included were in accordance with the ethical standards of the institutional board and with the 1964 Helsinki Declaration. This study is approved by the Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (approval no. [2022] 02-166-01). At admission, the subjects or the guardians of patients with cognitive impairment provided written informed consent for research and publication.